Patents
Literature
Patsnap Copilot is an intelligent assistant for R&D personnel, combined with Patent DNA, to facilitate innovative research.
Patsnap Copilot

45results about How to "Less soluble" patented technology

Insulin formulations for insulin release as a function of tissue glucose levels

Injectable insulin formulations that are capable of modifying the amount of insulin released based on the patient's tissue glucose levels, methods for making and using these formulations are described herein. The formulation may be administered via subcutaneous, intradermal or intramuscular administration. In one preferred embodiment, the formulations are administered via subcutaneous injection. The formulations contain insulin, an oxidizing agent or enzyme and a reducing agent or enzyme, a diluent and optionally one or more thickening agents. If a thickening agent is present in the formulation, the thickening agent increases the viscosity of the formulation following administration. Preferably the formulation contains an insulin, a diluent, glucose oxidase and peroxidase. Following administration to a patient, the insulin is released from the formulations as a function of the patient's tissue glucose level, which in turn maintains the patient's blood glucose level within an optimum range. The formulation is often referred to as a “smart” formulation since it modifies its release rate of insulin according to the patient's needs at a particular time. In a preferred embodiment, the formulation is designed to release insulin into the systemic circulation over time with a basal release profile following injection in a patient. In another embodiment, the formulation is designed to release insulin into the systemic circulation over time with a non-basal release profile following injection in a patient, such as a regular human insulin release profile or a prandial release profile.
Owner:BIODEL

Ionic Liquids Based on Imidazolium Salts Incorporating a Nitrile Functionality

Novel chemical compounds of the general formula
K+A,
in which K+is a 5- or 6-membered heterocyclic ring having 1-3 hetereo atoms, which can be independently N, S, or O;
with the proviso that at least one of the hetereo atoms must be a quaternized nitrogen atom having a —R′CN substituent, wherein R′ is alkyl (C1 to C12);
the heterocyclic ring having up to 4 or 5 substituents independently chosen from the moieties:
(i) H;
(ii) halogen or
(iii) alkyl (C1 to C12), which is unsubstituted or partially or fully substituted by further groups, preferably F, Cl, N(CnF(2n+1−x)Hx)2, O(CnF(2n+1−x)Hx), SO2(CnF(2n+1−x)Hx)2 or CnF(2n+1−x)Hx where 1<n<6 and 0<x<13; and
(iv) a phenyl ring which is unsubstituted or partially or fully substituted by further groups, preferably F, Cl, N(CnF(2n+1−x)Hx)2, O(CnF(2n+1−X)Hx), SO2(CnF(2n+1−x)Hx)2 or CnF(2n+1−x)Hx where 1<n<6 and 0<x≦13; and
Ais any anion that provides a salt with a low melting point, below about 100° C.; A can be halide, BF4−, PF6, NO3, CH3CO2, CF3SO3, (CF3SO2)2N, (CF3SO2)3C, CF3CO2 or N(CN)2 or [BF3RCN]
These compounds can be used as industrial solvents, especially as ligands for efficient catalyst recycling.
Owner:ECOLE POLYTECHNIQUE FEDERALE DE LAUSANNE (EPFL)
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products